抗HRSV融合蛋白参考抗体

Anti-HRSV Fusion Protein Reference Antibody

货号：RB9T37015295

在您使用本产品前请认真阅读说明书，这对您顺利完成实验很有帮助。

产品编码
RB9T37015295

中文名称
抗HRSV融合蛋白参考抗体

英文名称
Anti-HRSV Fusion Protein Reference Antibody

形态
Liquid

纯度
>95% purity as determined by SDS-PAGE.

内毒素水平
Please contact the lab for this information.

应用
ELISA, Bioactivity: FACS, Functional assay, Research in vivo

表达系统
Mammalian Cells

登录号
P03420

宿主种属
Humanized

克隆性
Monoclonal

抗体亚型
IgG1, kappa

纯化方式
Protein A/G purified from cell culture supernatant.

浓度
1mg/ml

种属反应性
HRSV-A

靶标

F, Fusion glycoprotein F0, Fusion glycoprotein F2, p27, Intervening segment, Pep27, Peptide 27, Fusion glycoprotein F1

背景信息

Palivizumab (brand name Synagis) is a humanized IgG monoclonal antibody (mAb) manufactured by MedImmune with recombinant DNA technology. It is used in the prevention of respiratory syncytial virus (RSV) infections. It is recommended for infants that are high-risk because of prematurity or other medical problems such as congenital heart disease. Palivizumab directed against an epitope in the A antigenic site of the F protein of RSV. Palivizumab is a composite of human (95%) and murine (5%) antibody sequences. The human heavy chain sequence was derived from the constant domains of human IgG1 and the variable framework regions of the VH genes Cor and Cess. The human light chain sequence was derived from the constant domain of Cκ and the variable framework regions of the VL gene K104 with Jκ -4. The murine sequences were derived from a murine monoclonal antibody, Mab 1129, in a process that involved the grafting of the murine complementarity determining regions into the human antibody frameworks. Palivizumab is composed of two heavy chains and two light chains and has a molecular weight of approximately 148, 000 Daltons. Palivizumab was approved for medical use in 1998 but the indications for prophylaxis vary worldwide. Palivizumab is primarily indicated for the following conditions: prematurity (gestational age ≤ 35 weeks), bronchopulmonary dysplasia/chronic lung disease, hemodynamically significant congenital heart disease, and other serious medical disorders on an ad hoc basis. Infants with these medical conditions are at increased risk of more severe disease and more serious subsequent sequelae.

别名

SB209763, HuRSV19VHFNS/VK, RSHZ19monoclonalantibody, SB209763, 167747-20-8

产品描述

Felvizumab [HuRSV19VHFNS/VK, RSHZ19, RSV monoclonal antibody, SB209763] is a humanised monoclonal antibody (IgG1) prepared by the humanization of an F protein-specific murine MAb. In in vitro studies, palivizumab, another humanized Mab specific for the F protein of RSV, was 4 to 5-fold more potent than felvizumab in neutralising RSV (Scott, 1999).

储存缓冲液

0.01M PBS, pH 7.4.

稳定性和储存

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4° C for short-term storage (1-2 weeks). Store at -20° C for up to 12 months. For long-term storage, store at -80° C.

For research use only. Not suitable for clinical or therapeutic use.